A Look At ICON (ICLR) Valuation After Q1 Earnings Miss And Recent Share Price Volatility

ICON (ICLR) is back in focus after first quarter results showed earnings per share of $3.29, slightly below analyst expectations, while revenue of $2.01b aligned with consensus estimates.

See our latest analysis for ICON.

The latest 1 day share price return of 2.49% and 7 day gain of 11.86% come after a much steeper 90 day share price decline of 42.21%, leaving 1 year total shareholder return at a 25.72% loss. This indicates that recent momentum has been more positive despite a weaker longer term record.

If ICON’s recent results have you reassessing opportunities in healthcare, it could be a moment to broaden your watchlist with 36 healthcare AI stocks

With earnings slightly below expectations, a share price still well below recent levels, and valuation markers such as an estimated intrinsic value gap and analyst targets in view, the key question is whether ICON is undervalued or if the market already reflects its future growth potential.

Most Popular Narrative: 20.1% Undervalued

ICON’s most followed valuation narrative pegs fair value at $142.86 versus a last close of $114.19, framing the recent selloff as creating a potential valuation gap to watch.

The updated analyst price target for ICON moves lower to $142.86 from $154.86, with analysts citing accounting-related uncertainty and potential backlog restatements, partially balanced by views that the recent selloff and current valuation may offer a more compelling risk and reward profile.

Read the complete narrative.

The core of this narrative is a recalibrated fair value built on more cautious revenue, margins and future earnings multiples. It still implies meaningful upside from today. Investors may be interested in which specific growth, profitability and valuation assumptions underpin that conclusion and how sensitive the outcome is to small tweaks.

Result: Fair Value of $142.86 (UNDERVALUED)

Have a read of the narrative in full and understand what’s behind the forecasts.

However, elevated trial cancellations and pricing pressure across CRO peers could still challenge ICON’s revenue resilience and keep margin expectations under scrutiny.

Find out about the key risks to this ICON narrative.

Next Steps

The split between concern about risks and interest in potential rewards is clear here. Move quickly, test the assumptions for yourself, and review the 3 key rewards and 2 important warning signs.

Looking for more investment ideas?

If ICON has sharpened your focus, do not stop here. Broaden your opportunity set with a few targeted stock ideas that fit different portfolio goals.

This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com